Evidence map›Paper›PMID 40755283›Full record

ReviewBriefings in bioinformatics2025

mRNA folding algorithms for structure and codon optimization.

Max Ward, Mary Richardson, Mihir Metkar

Abstract readReview
In one paragraph

Review in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. RNA therapeutics: current status and future directions.Signal transduction and targeted therapy · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Max WardSchool of Physics, Mathematics, and Computing, The University of Western Australia, WA 6009, Australia.ORCID 0000-0001-9114-7339
Mary RichardsonModerna, Inc., Cambridge, MA 02142, USA.ORCID 0000-0002-0177-6789
Mihir MetkarModerna, Inc., Cambridge, MA 02142, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

mRNA technology has revolutionized vaccine development, protein replacement therapies, and cancer immunotherapies, offering rapid production and precise control over sequence and efficacy. However, the inherent instability of mRNA poses significant challenges for drug storage and distribution, particularly in resource-limited regions. Co-optimizing RNA structure and codon choice has emerged as a promising strategy to enhance mRNA stability while preserving efficacy. Given the vast sequence and structure design space, specialized algorithms are essential to achieve these qualities. Recently, several effective algorithms have been developed to tackle this challenge that all use similar underlying principles. We call these specialized methods mRNA folding algorithms as they generalize classical RNA folding algorithms. Initial laboratory testing of mRNA folding optimized mRNA vaccines, such as those encoding SARS-CoV-2 spike and VZV gE, has shown promising improvements in both in-solution stability and immunogenicity. While these biological properties are beginning to be evaluated experimentally, a comprehensive in silico analysis of the underlying principles, performance, and limitations of these design algorithms is equally essential. Thus, this review aims to provide an in-depth understanding of these algorithms, identify opportunities for improvement, and benchmark existing software implementations in terms of scalability, correctness, and feature support.

Indexed as

AlgorithmsCodonRNA FoldingRNA, MessengerCOVID-19HumansNucleic Acid ConformationSARS-CoV-2CodonRNA, Messengeralgorithm benchmarkingalgorithmsdynamic programmingmRNA foldingmRNA optimizationmRNA therapeuticsRNARNA secondary structure

Identifiers

PMID40755283
PMCPMC12319323

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.